Business Description
Helus Pharma Inc
NAICS : 541720
SIC : 3741
ISIN : CA23256X1006
Share Class Description:
STU:R7E: Ordinary SharesTotal Employee Number:
50Description
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.4 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.2 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 19.2 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | 20.4 | |||||
3-Year Book Growth Rate | -13.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.46 | |||||
9-Day RSI | 75.3 | |||||
14-Day RSI | 72.45 | |||||
3-1 Month Momentum % | -14.83 | |||||
6-1 Month Momentum % | -40.83 | |||||
12-1 Month Momentum % | -38.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.52 | |||||
Quick Ratio | 9.52 | |||||
Cash Ratio | 8.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -115.6 | |||||
Shareholder Yield % | -39.52 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -76.41 | |||||
ROA % | -66.03 | |||||
ROIC % | -183.17 | |||||
3-Year ROIIC % | -204.18 | |||||
ROC (Joel Greenblatt) % | -1296.12 | |||||
ROCE % | -68.42 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.66 | |||||
Price-to-Tangible-Book | 2.33 | |||||
EV-to-EBIT | -2.84 | |||||
EV-to-EBITDA | -2.84 | |||||
EV-to-Forward-EBITDA | -1.97 | |||||
EV-to-Forward-Revenue | 1.07 | |||||
EV-to-FCF | -3 | |||||
| Price-to-Net-Current-Asset-Value | 2.33 | |||||
| Price-to-Net-Cash | 2.79 | |||||
Earnings Yield (Greenblatt) % | -35.21 | |||||
FCF Yield % | -29.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Helus Pharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.727 | ||
| Beta | -1.5914 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 89.97 | ||
| 14-Day RSI | 72.45 | ||
| 14-Day ATR (€) | 0.404645 | ||
| 20-Day SMA (€) | 5.4485 | ||
| 12-1 Month Momentum % | -38.03 | ||
| 52-Week Range (€) | 3.22 - 7.55 | ||
| Shares Outstanding (Mil) | 61.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Helus Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Helus Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-13 08:00 | In 119 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 118 days | ||
| General meeting for 2026 | 2026-08-18 10:00 | In 32 days | ||
| First quarter earnings results for 2027 | 2026-08-13 | In 26 days | ||
| Annual report for 2026 | 2026-06-29 | 5.59 (+7.09%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-25 | 4.41 (+5.26%) | ||
| H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference | 2026-06-15 07:00 | 3.72 (+8.30%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 14:35 | 3.68 (-4.30%) | ||
| Milken Institute Global Conference | 2026-05-04 14:30 | 4.47 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-02-13 | 4.96 (-8.15%) |
Show
Entries
Helus Pharma Inc Frequently Asked Questions
What is Helus Pharma Inc(STU:R7E)'s stock price today?
The current price of STU:R7E is €6.39. The 52 week high of STU:R7E is €7.55 and 52 week low is €3.22.
When is next earnings date of Helus Pharma Inc(STU:R7E)?
The next earnings date of Helus Pharma Inc(STU:R7E) is 2026-08-13 Est..
Does Helus Pharma Inc(STU:R7E) pay dividends? If so, how much?
Helus Pharma Inc(STU:R7E) does not pay dividend.
Press Release
Articles on Helus Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers